Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

4.640 -0.610 (-11.62%)
Streaming Delayed Price Updated: 9:45 AM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
AbCellera Biologics Q1 Earnings Call Highlights ↗
AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued... 
Via MarketBeat
Topics Earnings
News headline image
AbCellera (ABCL) Q1 2026 Earnings Transcript ↗
AbCellera (ABCL) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall ↗
Via Chartmill
Topics Intellectual Property
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
CRA: Here’s the TFSA Contribution Room for 2026 and Why Now Is the Best Time to Use It ↗
The CRA confirmed $7,000 in TFSA room for 2026. Here's why AbCellera Biologics could be one of the smartest growth stocks to put that money to work in right now. 
Via The Motley Fool
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
AbCellera Reports Full Year 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera and Bruker Reach Global Settlement of Patent Litigation
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday? ↗
Risk-off sentiment dominated Wall Street on Friday, with selling pressure in AI-linked names intensifying and pushing technology stocks toward their worst week since April. 
Via Benzinga
Topics Artificial Intelligence
News headline image
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗
AbCellera's Q3 2025 results show revenue beat estimates, but the net loss widened, causing a negative after-hours stock reaction. 
Via Chartmill
News headline image
AbCellera Reports Q3 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus ↗
U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed. 
Via Benzinga
Topics Stocks
News headline image
AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? ↗
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Why Did AbCellera's Stock Jump Over 7% After Hours? ↗
AbCellera's stock rose 7.72% in after-hours trading following an 18.49% gain during regular trading, with a strong performance expected in Q3 earnings. 
Via Benzinga
News headline image
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
From AbCellera Biologics Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.